Form 8-K - Current report:
SEC Accession No. 0001628280-25-013984
Filing Date
2025-03-20
Accepted
2025-03-20 07:02:04
Documents
15
Period of Report
2025-03-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20250320.htm   iXBRL 8-K 26897
2 EX-99.1 ex-991fy2024earningsrelease.htm EX-99.1 99734
6 GRAPHIC avalo-logoxblk1.jpg GRAPHIC 99614
  Complete submission text file 0001628280-25-013984.txt   395840

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20250320.xsd EX-101.SCH 1850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20250320_lab.xml EX-101.LAB 21026
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20250320_pre.xml EX-101.PRE 12041
17 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20250320_htm.xml XML 2625
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 25754462
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)